Sodium oxybate for the treatment of narcolepsy.
Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin re-uptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.
Thorpy
Michael J
MJ
Montefiore Medical Center, Sleep-Wake Disorders Center and Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY 10467, USA. thorpy@aecom.yu.edu
D002385:Cataplexy / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D009290:Narcolepsy / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012890:Sleep / Q000187:drug effects / Q000502:physiology; D012978:Sodium Oxybate / Q000493:pharmacokinetics / Q000627:therapeutic use*
D012978:Sodium Oxybate